Document Detail


Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy.
MedLine Citation:
PMID:  6962628     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The combined treatment with phlebotomy and high-dose chloroquine for PCT is described and 21 patients treated were followed up for periods of up to 6 years. Clinical and laboratory remissions were experienced by all patients. The urinary excretion of porphyrin and serum hepatic enzyme levels rose rapidly during therapy and then fell, mostly to levels well below that before treatment. The periods required for normalization of laboratory tests, median value, were 1.5 months for liver enzymes and 7 months for uroporphyrins. Clinical symptoms soon disappeared, blistering within 3 weeks and skin fragility within 12. Mild nausea or subfebrility was noted in some cases, but no other serious acute or chronic adverse reactions were observed. Clinical or biochemical relapse appeared in 9/21 (43%) patients who were then retreated. Relapsing cases showed a symptomfree period of 1-2.5 years after each treatment. Liver biopsy was performed in 4 relapsing cases prior to the repeated treatment and showed only mild siderosis and a mild fatty infiltration consistent with pathological liver findings in PCT but no evidence of chloroquine-induced permanent liver damage. The longest symptomfree period observed up to date was assessed for 7 patients who were followed up for more than 2 years after 1 single treatment. Four (57%) of them were symptomfree 5-6 years and no clinical or biochemical signs of relapse were observed. Our data confirm the efficacy of the high-dose therapeutic procedure, and the combined regimen with 1-2 phlebotomies prior to the chloroquine administration seems to be a safe procedure without any serious side effects. Our findings are discussed in relation to other current therapeutic modalities.
Authors:
G Wennersten; A M Ros
Related Documents :
6456288 - Initial 6-month follow-up of patients with major depressive disorder. a preliminary rep...
20952228 - Prevention of relapse following intraoral vertical ramus osteotomy mandibular setback: ...
22748448 - Changing expectations for neurological outcomes after the neonatal arterial switch oper...
22505908 - Fe-sem evaluation of dental specimens prepared by different methods for in vitro contam...
8808958 - Does donor iliac artery percutaneous transluminal angioplasty or stent placement influe...
17151898 - Self-expandable metallic stents as palliative treatment for malignant colorectal obstru...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta dermato-venereologica. Supplementum     Volume:  100     ISSN:  0365-8341     ISO Abbreviation:  Acta Derm Venereol Suppl (Stockh)     Publication Date:  1982  
Date Detail:
Created Date:  1983-04-15     Completed Date:  1983-04-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370311     Medline TA:  Acta Derm Venereol Suppl (Stockh)     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  119-23     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bloodletting*
Chloroquine / administration & dosage*,  therapeutic use
Female
Follow-Up Studies
Humans
Liver / enzymology
Male
Middle Aged
Porphyrias / therapy*
Recurrence
Skin Diseases / therapy*
Time Factors
Uroporphyrins / urine
Chemical
Reg. No./Substance:
0/Uroporphyrins; 54-05-7/Chloroquine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phlebotomy treatment of porphyria cutanea tarda.
Next Document:  Environmental and drug factors in hepatic porphyria.